The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?
Featured:
Mikkael A. SekeresDuring the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US. We asked, What do the PANTHER trial results tell us about first-line treatment for high-risk myelodysplastic syndromes (MDS)?
What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?
In this video, Sekeres discusses the randomized phase III PANTHER trial (NCT03268954), which investigated pevonedistat + azacitidine versus single-agent azacitidine as first-line treatment for patients with higher risk MDS, chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (AML).